Mirae Asset Global Investments’s Sutro Biopharma STRO Stock Holding History

Mirae Asset Global Investments’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-328	Closed	-$2.85K	–	1740
2025 Q3	$2.85K	Buy	328 +2	+0.6%	+$17	﹤0.01%	1626
2025 Q2	$2.33K	Buy	326 +58	+22%	+$474	﹤0.01%	1564
2025 Q1	$1.97K	Sell	268 -7	-3%	-$110	﹤0.01%	1539
2024 Q4	$5.19K	Buy	+275	New	+$8.39K	﹤0.01%	1557
2024 Q2	–	Sell	-4,402	Closed	-$202K	–	2419
2024 Q1	$202K	Buy	+4,402	New	+$194K	﹤0.01%	2259
2023 Q4	–	Sell	-4,544	Closed	-$158K	–	2597
2023 Q3	$158K	Buy	4,544 +5	+0.1%	+$218	﹤0.01%	2362
2023 Q2	$211K	Sell	4,539 -822	-15%	-$40.9K	﹤0.01%	2314
2023 Q1	$248K	Buy	5,361 +3,424	+177%	+$217K	﹤0.01%	2254
2022 Q4	$157K	Buy	1,937 +15	+0.8%	+$1.04K	﹤0.01%	2356
2022 Q3	$106K	Buy	1,922 +571	+42%	+$33.8K	﹤0.01%	2493
2022 Q2	$70K	Buy	+1,351	New	+$75.5K	﹤0.01%	2355

Other funds holding STRO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Mirae Asset Global Investments's STRO Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 328 shares — an estimated $2.85K sold.

Mirae Asset Global Investments first reported a position in STRO in Q2 2022 and held it in 11 quarters. The position peaked at $248K in Q1 2023. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

Mirae Asset Global Investments reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
Mirae Asset Global Investments sold 328 Sutro Biopharma shares in Q4 2025, an estimated $2.85K.
Mirae Asset Global Investments first reported a position in Sutro Biopharma in Q2 2022 and held it in 11 quarters.
Mirae Asset Global Investments's Sutro Biopharma position peaked at $248K in Q1 2023.
63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.